Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

NCT03033524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

DRUG: TTAC-0001

Sponsor

PharmAbcine